LFCR maintains full-year guidance and forecasts fill/finish demand to double in 2027 and grow over 200% by 2028.
Lifecore Biomedical reaffirmed its 2026 guidance during its Q2 2026 earnings call, citing execution of its three-pillar growth strategy. The company expressed confidence in meeting full-year expectations despite market conditions.
Management outlined a sharp rise in fill/finish demand, projecting it to double in 2027 and grow more than 200% by 2028. The outlook reflects anticipated expansion in biopharmaceutical manufacturing and contract development services.
No immediate market reaction was disclosed in the call summary. Lifecore’s guidance reaffirmation follows prior projections shared earlier in the year.